Eucomed publication on regenerative medicine & tissue engineering
This article was originally published in Clinica
Eucomed has launched the second in a series of educational publications on medical technology innovation, focusing on regenerative medicine and human tissue engineering. The booklet points out that there is still a lack of effective regulatory framework, and Eucomed says that "such future legislation must be designed in a way to allow research and innovation in the field to flourish and the prospect of a timely return on research investment to be realised, whilst at the same time ensuring risks to patients are minimised and that equitable access to treatment can be attained".
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.